Phase 1 Patient 1080-001:
Long Lasting Benefit in mCRC >5 years
PET/CT before BXQ-350
PET/CT after 18 months on BXQ-350
40-yr old female with stage 4 metastatic colorectal carcinoma
Diagnosed in Nov 2015, previously treated with surgery, chemotherapy and radiation (>3 lines)
Rapid progression (5 months) prior to starting BXQ-350
Target lesion (1.5 cm) remained unchanged per Recist
Still Stable Disease over 5 years on study
Phase 1 Patient 1008-701:
Long Lasting Benefit in GBM > 5 years!
Red Arrows indicate the initial target lesion that decreased in size while on study
Blue Arrows indicate new area of enhancement
Note: Surgery in May, 2018 revealed significant treatment effect with only trace tumor cells present. As of September, 2019 patient continues on study having completed 3 years in the trial.
Case Data: Glioblastoma (GBM)
Axial T1-post contrast (Ax SE T1 POST FC) 1.5T MRI of the brain of a 64-yr old male patient with glioblastoma (GBM) treated with BXQ-350. GBM was first diagnosed in 2013 and previously treated with surgery, chemotherapy and radiation. Measurable lesion reduction over time is apparent in the anterior corpus callosum and frontal lobe, with those bordering the ventricle.
Phase 1 Patient 1075-213:
Partial Response in Glioblastoma (-74%)
65-yr old female with rGBM
GBM diagnosed in March 2017 (stage IV) previously treated with surgery, chemotherapy and radiation
Rapid progression (2M) prior to starting BXQ-350 in May 2018
1 target lesion (L parietal) 1.4 cm at Screening down to 0.36 cm at Day 56 (-74%)